Phase 1 Trial of the Safety, Pharmacokinetics, and Antiviral Activity of EDP-514 in Untreated Viremic Chronic Hepatitis B Patients
CONCLUSIONS: In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.PMID:38528825 | DOI:10.3350/cmh.2023.0535 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 26, 2024 Category: Gastroenterology Authors: Man-Fung Yuen Wan-Long Chuang Cheng-Yuan Peng Wen-Juei Jeng Wei-Wen Su Ting-Tsung Chang Chi-Yi Chen Yao-Chun Hsu Guy De La Rosa Alaa Ahmad Ed Luo Annie L Conery Source Type: research

Both Liver Parenchymal and Non-Parenchymal Cells Express JCAD Proteins under Various Circumstances
Clin Mol Hepatol. 2024 Mar 20. doi: 10.3350/cmh.2024.0191. Online ahead of print.NO ABSTRACTPMID:38503552 | DOI:10.3350/cmh.2024.0191 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 19, 2024 Category: Gastroenterology Authors: Li Xie Li Zhang Hui Chen Yong-Yu Yang Jian Wu Source Type: research

Reply to: "Evaluation of the histological scoring systems of autoimmune hepatitis: a significant step towards the optimization of clinical diagnosis"
Clin Mol Hepatol. 2024 Mar 19. doi: 10.3350/cmh.2024.0180. Online ahead of print.NO ABSTRACTPMID:38499439 | DOI:10.3350/cmh.2024.0180 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 18, 2024 Category: Gastroenterology Authors: Haeryoung Kim Sook-Hyang Jeong Source Type: research

Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
CONCLUSIONS: Our buffy coat WTS data and plasma proteome data may serve as reliable sources for identifying etiology-specific blood biomarkers of HCC and might contribute to discovery of therapeutic targets for HCC across different etiologies.PMID:38486508 | DOI:10.3350/cmh.2024.0042 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 15, 2024 Category: Gastroenterology Authors: Jiwon Hong Jung Woo Eun Geum Ok Baek Jae Youn Cheong Seryoung Park Soon Sun Kim Hyo Jung Cho Su Bin Lim Source Type: research

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study
CONCLUSION: In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.PMID:38468561 | DOI:10.3350/cmh.2023.0553 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 12, 2024 Category: Gastroenterology Authors: Young Eun Chon Dong Yun Kim Mina Kim Beom Kyung Kim Seung Up Kim Jun Yong Park Sang Hoon Ahn Yeonjung Ha Joo Ho Lee Kwan Sik Lee Beodeul Kang Jung Sun Kim Hong Jae Chon Do Young Kim Source Type: research

Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Clin Mol Hepatol. 2024 Jan 30. doi: 10.3350/cmh.2024.0028. Online ahead of print.NO ABSTRACTPMID:38471499 | DOI:10.3350/cmh.2024.0028 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - March 12, 2024 Category: Gastroenterology Authors: Tsubasa Tsutsumi Dan Nakano Machiko Kawaguchi Hirokazu Takahashi Takumi Kawaguchi Source Type: research